Condition: Ischemic Heart Failure · Sponsor: BioCardia, Inc.
Concentrated autologous bone marrow mononuclear cells (ABM MNC) contain potentially therapeutic cell factors and past studies support therapeutic benefit to patients with cardiac diseases of acute myocardial infarction, ischemia, and heart failure when utilized as this study is designed. The purpose of the study is to determine the safety and efficacy of CardiAMP cell therapy system in patients with ischemic heart failure. It is a prospective, multi-center, randomized, controlled, patient and evaluator-blinded study comparing treatment with the CardiAMP cell therapy system to a control procedure with diagnostic catheterization.
This description comes directly from the study's public registry record.
Debby Holmes-Higgin, MS, MPH · 650-226-0120 · debbyhh@biocardia.com
Always discuss trial participation with your own doctor first.
| Morton Plant Hospital - BayCare | Clearwater, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Henry Ford Hospital | Detroit, Michigan, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Withdrawn |
| University of Wisconsin-Division of Cardiovascular Medicine | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06258447